A Phase 1 Study of AZD1775 in Combination With Belinostat in Relapsed and Refractory Myeloid Malignancies and Selected Untreated Patients With Acute Myeloid Leukemia
Phase of Trial: Phase I
Latest Information Update: 17 Aug 2017
At a glance
- Drugs AZD-1775 (Primary) ; Belinostat (Primary)
- Indications Acute myeloid leukaemia; Chronic myeloid leukaemia; Myelodysplastic syndromes
- Focus Adverse reactions
- 10 Jun 2017 Biomarkers information updated
- 26 Jan 2017 Planned number of patients changed from 13 to 30.
- 26 Jan 2017 Planned primary completion date changed from 1 Oct 2016 to 1 Aug 2018.